NHS England published interim commissioning guidance for tirzepatide
Guidance covering implementation of NICE TA1026 for tirzepatide in obesity was published, setting out the requirement for wrap-around care alongside prescribing. NICE guidance effectively mandates that support, so tirzepatide is not funded as a standalone treatment.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.